MONROE TOWNSHIP, N.J., March 29, 2021 /PRNewswire/ — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today a new partnership with CardioNavix, LLC aimed at improving patient access to cardiac PET imaging, an important diagnostic test for the detection of coronary artery disease (CAD). This new program, the Bracco Mobile Isotope Service, will enable more patient care sites, such as community hospitals, physician practices and outpatient imaging centers, to provide cardiac PET imaging.
Kim McDaniel, Sr. Director, Nuclear Medicine Sales and Market Support said, “Establishing a cardiac PET imaging program requires significant upfront and ongoing costs that a provider must be able to recover. This can make the modality challenging to implement for institutions with lower patient volumes due to location or the need to share equipment with oncology studies. This new program will help lower the upfront cost and business risk, to allow more healthcare providers to offer this important diagnostic test. Our Bracco Mobile Isotope Service and partnership with CardioNavix is another example of our commitment to increase patient access to cardiac PET imaging.”
Bracco Mobile Isotope Service On-Demand Delivery Program Increases Flexibility, Decreases Upfront Business Risk
Bracco has traditionally offered CardioGen-82® (Rubidium Rb 82 Generator) and its accompanying infusion system to its more…